In the double-choice trials, preference was higher for FS relative to BT (61%–39%), and for N relative to BT (62%38%%), but similar between FS and N (57%–43%).
We found that over 5 days with one session of 20 trials, preference for the 6-pellet compartment steadily increased reaching 84±2% by the last day.
Eligible study designs include randomised controlled trials, cluster randomised controlled trials, staggered enrolment trials, stepped wedged trials, quasi-randomised trials, quasi-experimental trials, time series/interrupted time-series trials, preference trials, regression discontinuity trials and natural experiment studies with a parallel control group.
In some early phase trials, preference based measures are not usually collected, but condition specific measures such as the QLQ-C30 are collected to provide early indications of symptom control for future phase II/III trial planning, particularly for re-imbursement.
We did our first search on the terms "random, trial, preference, Torgerson, Sibbald" and a second search on the terms "random, trial, preference, Torgerson, Klaber".
Principally, we could not include placebos to allow a no-treatment condition or to blind treatment allocation and, although we waited until all treatments had long become routine before conducting the trial, preference bias remains a possibility.
The contributions of these two learning rules to trial-by-trial preference adjustments are distinguishable when learning multistep decision tasks, and the hallmarks of both rules have been reported in both human (Daw, Gershman, Seymour, Dayan, & Dolan, 2011) and rodent (Akam, Dayan, & Costa, 2013; Miller, Erlich, Kopec, Botvinick, & Brody, 2014) behavior.
In the absence of biomarkers predictive for activity, patients are currently selected based on eligibility criteria in pivotal phase III trials, patient preferences, toxicity profiles, comorbidities and costs.
This prospective, open-label, multicenter trial compared preferences for buprenorphine and buprenorphine/naloxone in 53 opioid-dependent patients stabilized on buprenorphine.
